![4-Hydroxy-Alpha1-[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol](https://static.cymitquimica.com/products/TR/img/H949145.png "Click to enlarge")
4-Hydroxy-Alpha1-[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol
CAS: 94749-02-7
Ref. TR-H949145
| 25mg | 1,749.00 € | ||
| 2500µg | 260.00 € |
Estimated delivery in United States, on Tuesday 25 Jun 2024
Product Information
Name:
4-Hydroxy-Alpha1-[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol
Synonyms:
- Salmeterol Xinafoate Imp. B (EP)
- (1RS)-1-[4-Hydroxy-3-(hydroxymethyl)phenyl]-2-[[6-(2-phenylethoxy)hexyl]amino]ethanol
- GR 31354X
- Salmeterol Xinafoate Impurity B
- Salmeterol Impurity B
CAS:
Description:
Impurity Salmeterol EP impurity B
Applications 4-Hydroxy-α1-[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (Salmeterol EP impurity B) is an impurity of Salmeterol (S090100), a β2-adrenergic agonist structural analog of Albuterol (A514500).
References Johnson, M.: Lung, 168, Suppl., 115 (1990), Ullman, A., et al.: Am. Rev. Resp. Dis., 142, 571 (1990), Twentyman, O.P., et al.: Lancet, 336, 1338 (1990)
Brand:
TRC
Long term storage:
Notes:
Chemical properties
Molecular weight:
387.51
Formula:
C23H33NO4
Color/Form:
White to Off-White Solid
InChI:
InChI=1S/C23H33NO4/c25-18-21-16-20(10-11-22(21)26)23(27)17-24-13-6-1-2-7-14-28-15-12-19-8-4-3-5-9-19/h3-5,8-11,16,23-27H,1-2,6-7,12-15,17-18H2
InChI key:
InChIKey=SFLNGSUKAXWYTL-UHFFFAOYSA-N
SMILES:
OCc1cc(C(O)CNCCCCCCOCCc2ccccc2)ccc1O
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TR-H949145 4-Hydroxy-Alpha1-[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
